via Tel Aviv University
Novel RNA technology – Boosting personalized cancer care
Researchers from Tel Aviv University proved that a drug delivery system based on lipid nanoparticles can utilize RNA to overcome resistance to both chemotherapy and immunotherapy in cancer treatments. The study opens a new path to a personalized and precisely targeted battle against cancer. The results were published in the scientific journal Advanced Materials.
The study was led by TAU Vice President for R&D Prof. Dan Peer, Head of the Laboratory of Precision Nanomedicine at the Shmunis School of Biomedicine and Cancer Research, Wise Faculty of Life Sciences, and a member of the Roman Abramovich Center for Nanoscience and Nanotechnology, together with post-doctoral researcher Dr. Seok-Beom Yong of South Korea. The study was funded via an ERC grant from the European Union and a research scholarship from the Korean government.
Chemo-immunotherapy, which combines chemotherapy with immunotherapy, is considered the most advanced standard of care for various types of cancer. While chemotherapy destroys cancer cells, immunotherapy encourages the cells of the immune system to identify and attack the remaining cancer cells. However, many patients fail to respond to chemo-immunotherapy, which means that the treatment is not sufficiently targeted. Prof. Peer and his team are the first in the world to prove the feasibility of a drug delivery system based on lipid nanoparticles that release their load only at the specifically targeted cells – cancer cells for chemotherapy and immune cells for immunotherapy.
“In our system a single nanoparticle is capable of operating in two different arenas,” explains Prof. Peer. “It increases the sensitivity of cancer cells resistant to chemotherapy, while also reinvigorating immune cells and increasing their sensitivity to cancer cells. Thus, with one precisely targeted nanoparticle we provide two different treatments, at very different sites. We tested this system in two types of lab models – one for metastasized melanoma, and the other for a local solid tumor. In both populations we observed positive effects of our delivery system.”
The new development by Prof. Peer’s team builds from another recent discovery: an enzyme called HO1 is used by cancer cells for both resisting chemotherapy and concealing themselves from the immune system. Silencing HO1 in the tumor is thus considered an optimal strategy in clinical research, but so far, all attempts to silence the enzyme led to severe side effects.
“Chemo-resistant tumors pose a significant challenge in our endless battle against cancer,” says Prof. Peer. “We aim to silence the enzyme HO1 which enables tumors to develop resistance to chemotherapy, and to conceal themselves from the immune system. But existing methods for silencing HO1 resemble using an F-16 fighter jet to blast a tiny ant. Our new nanodrug knows how to precisely target the cancer cells, silence the enzyme, and expose the tumor to chemotherapy, without causing any damage to surrounding healthy cells. Afterwards, the same nanoparticle goes on to the T-cells of the immune system and reprograms them to identify cancer cells. Active, highly aggressive tumors are able to conceal themselves from the immune system, and we restore the immune cells’ ability to recognize the cancer as a foreign body and attack it.”
“This is the first instance of a single drug based on an RNA-loaded nanoparticle doing two very different, even opposite jobs,” adds Prof. Peer. “This is only an initial study, but it has enormous potential in the ongoing fight against cancer.”
More from: Tel Aviv University
The Latest on: RNA technology
- Study finds CRISPR technology may provide novel treatment for genetic disorderson July 5, 2022 at 8:46 pm
New research revealed that one of the major issues faced by modern medicine is the treatment of crippling hereditary illnesses The introduction of CRISPR techn ...
- Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapieson July 5, 2022 at 4:02 pm
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer. Under the ...
- CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patentson July 5, 2022 at 2:03 pm
Messenger RNA vaccine biotech CureVac is suing BioNTech, alleging that its rival’s Covid-19 vaccine infringes on intellectual property built on more than two decades of research. BioNTech responded ...
- EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNSon July 5, 2022 at 7:36 am
EditForce and MTPC are to collaborate on gene therapy products for a specific target disease related to the central nervous system.
- CureVac sues BioNTech in Germany for infringement of mRNA technology patentson July 5, 2022 at 5:10 am
CUREVAC, a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, has begun legal proceedings against BioNTech in Germany “seeking fair compensation for infringement of a ...
- EditForce and Mitsubishi Tanabe Pharma Enter into License Agreementon July 5, 2022 at 12:00 am
EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") ...
- IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergieson July 1, 2022 at 6:02 am
IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery ...
- Antisense and RNAi Therapeutics Market Size, Share, Growth Status, Prominent Players, and Forecast 2028on June 30, 2022 at 8:14 am
The Global Antisense and RNAi Therapeutics Market is expected to register a CAGR of over 7.3% during the forecast period ...
- Investigating the prerequisites for developing RNA-based antibioticson June 28, 2022 at 9:59 pm
In the fight against the Covid-19 pandemic, mRNA-based vaccines have impressively demonstrated their potential. Using this technology, scientists were able to rapidly develop and bring to market ...
- Terminator Upgrades Single-Cell RNA Sequencing Technologyon June 28, 2022 at 5:00 am
Japanese scientists have developed a new method for DNA amplification and sequencing that improves the accuracy of single-cell RNA sequencing (scRNA-seq). The new method called TAS-Seq uses a terminal ...
via Bing News
The Latest on: RNA technology
via Google News